Status:
RECRUITING
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Lead Sponsor:
iOMEDICO AG
Conditions:
Chronic Lymphocytic Leukemia (CLL)
Diffuse Large B-cell Lymphoma (DLBCL)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of...
Detailed Description
RUBIN is a national, observational, prospective, longitudinal, multicenter registry platform with the purpose to record information on the antineoplastic treatment of hematological malignancies in Ger...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Confirmed diagnosis of the respective NHL
- If patient is alive: signed written informed consent
- For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
- For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
Exclusion
- No systemic therapy for respective lymphoid malignancy.
Key Trial Info
Start Date :
September 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2033
Estimated Enrollment :
2950 Patients enrolled
Trial Details
Trial ID
NCT06043011
Start Date
September 27 2023
End Date
December 1 2033
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Praxis für Interdisziplinäre Hämatologie und Onkologie
Freiburg im Breisgau, Germany